This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ITUS ITUS (ITUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ITUS Stock (NASDAQ:ITUS) 30 days 90 days 365 days Advanced Chart Remove Ads Get ITUS alerts:Sign Up Key Stats Today's Range$4.61▼$4.7650-Day Range N/A52-Week Range$1.83▼$6.43Volume69,859 shsAverage Volume134,373 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAnixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.Read More… Remove Ads Receive ITUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ITUS and its competitors with MarketBeat's FREE daily newsletter. Email Address ITUS Stock News HeadlinesIn The Spotlight: Clare is challenging status quo in cyber securityFebruary 3, 2025 | msn.comGMFS Itus Virtus Underground Toy Drive!December 4, 2024 | msn.comWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.April 10, 2025 | Altimetry (Ad)US recession coming in 2025? How will it affect the stock markets? Here's how to navigate itNovember 7, 2024 | msn.com6 arrested in Titus County following investigation into child trafficking, prostitutionNovember 2, 2024 | msn.comSherlock wins FR Americas Race 1 at COTANovember 2, 2024 | msn.comUS Election 2024: ‘Smart, tough, trusted’: Joe Biden’s high praise for Kamala Harris, says Trump lacks these qualitiesOctober 29, 2024 | msn.comTop events on October 15: PM Modi to inaugurate ITU's telecom meet, PVR Inox Q2 results, Jaishankar in Pakistan and moreOctober 15, 2024 | msn.comSee More Headlines ITUS Stock Analysis - Frequently Asked Questions How were ITUS's earnings last quarter? ITUS Co. (NASDAQ:ITUS) issued its quarterly earnings results on Friday, March, 9th. The business services provider reported ($0.11) EPS for the quarter. What other stocks do shareholders of ITUS own? Based on aggregate information from My MarketBeat watchlists, some other companies that ITUS investors own include Synergy Pharmaceuticals (SGYP), Galectin Therapeutics (GALT), Catalyst Pharmaceuticals (CPRX), Halozyme Therapeutics (HALO), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN) and Anixa Biosciences (ANIX). Company Calendar Last Earnings3/09/2018Today4/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Patent Owners & Lessors Sub-IndustryN/A Current SymbolNASDAQ:ITUS CIK715446 Webwww.ituscorp.com Phone(408) 708-9808FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ITUS) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersThe Most Bullish Metric For Stocks (NOT Volume…)Before placing a single trade, Tim Sykes always checks one key bullish metric. It’s the same signal that has s...MillPub | SponsoredTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy crypto may be the best way to play this chaotic market …Wall Street is in chaos … Over $6 trillion was wiped … in just two days. But something else was happenin...Weiss Ratings | SponsoredBITCOINYou're not going to believe this. There's a bizarre new way to make money from crypto... ...and it's not...Awesomely, LLC | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ITUS Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ITUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
